Focus on Heart Failure | SGLT2 Inhibitors in Heart Failure: The EMPEROR DELIVERs His SOLO - American College of Cardiology
Diabetes drug dapagliflozin may benefit patients with heart failure
Figure taken from McMurray J, et al. Dapagliflozin in Patients with... | Download Scientific Diagram
DAPA ACT HF-TIMI 68 – TIMI STUDY GROUP
FDA Clears Dapagliflozin to Reduce Heart Failure Hospitalizations | DAIC
Dapagliflozin Benefits Patients with Mildly Reduced and Preserved Ejection Fraction | DAIC
Dapagliflozin approved in EU for heart failure across full ejection fraction spectrum - Hospital Pharmacy EuropeHospital Pharmacy Europe
Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions - ScienceDirect
2.6 – Heart failure – Somerset Prescribing Formulary
A new indication and clinical criteria have been added to the PBS listing for dapagliflozin
Dosage and administration of SGLT2 inhibitors according to renal... | Download Table
Management of heart failure with reduced ejection fraction in 2021: an update for GPs | British Journal of General Practice
Forxiga 10 mg film-coated tablets - Summary of Product Characteristics (SmPC) - (emc)
SGLT2 Inhibitors in Heart Failure: DAPA-HF & EMPEROR Trials
Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects - Journal of Molecular and Cellular Cardiology
Treating Type 2 Diabetes to Improve Cardiovascular Health - U.S. Medicine
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial | Nature Medicine
Pharmaceutics | Free Full-Text | The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | NEJM
FDA Approves Diabetes Medication for Heart Failure - Diabetes Education Services
European Society of Cardiology on X: "Early initiation of the sodium glucose co-transporter 2 (#SGLT2) inhibitor dapagliflozin did not result in a statistically significant improvement in diuretic efficiency relative to structured usual
SGLT2 Inhibitors and Heart Failure Outcomes
Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan - Yang - 2022 - European Journal of Heart Failure - Wiley Online Library
Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure - ScienceDirect
In Brief: Expanded Heart Failure Indication for Dapagliflozin (Farxiga) | The Medical Letter Inc.
Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction | Journal of the American College of Cardiology
